10q10k10q10k.net
TREACE MEDICAL CONCEPTS, INC.

TREACE MEDICAL CONCEPTS, INC.TMCIEarnings & Financial Report

Nasdaq

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

TMCI Q3 2025 Key Financial Metrics

Revenue

$50.2M

Gross Profit

$39.7M

Operating Profit

$-15.7M

Net Profit

$-16.3M

Gross Margin

79.1%

Operating Margin

-31.2%

Net Margin

-32.4%

YoY Growth

11.4%

EPS

$-0.26

Financial Flow

TREACE MEDICAL CONCEPTS, INC. Q3 2025 Financial Summary

TREACE MEDICAL CONCEPTS, INC. reported revenue of $50.2M for Q3 2025, with a net profit of $-16.3M (-32.4% margin). Cost of goods sold was $10.5M, operating expenses totaled $55.4M.

Key Financial Metrics

Total Revenue$50.2M
Net Profit$-16.3M
Gross Margin79.1%
Operating Margin-31.2%
Report PeriodQ3 2025

TREACE MEDICAL CONCEPTS, INC. Annual Revenue by Year

TREACE MEDICAL CONCEPTS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $209.4M).

YearAnnual Revenue
2024$209.4M
2023$187.1M
2022$141.8M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$62.2M$51.1M$44.5M$45.1M$68.7M$52.6M$47.4M$50.2M
YoY Growth25.0%21.1%6.0%10.6%10.4%2.9%6.6%11.4%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$251.9M$242.7M$226.1M$212.9M$217.1M$205.8M$206.4M$196.6M
Liabilities$114.0M$116.3M$113.9M$108.0M$104.2M$100.5M$108.8M$107.4M
Equity$137.9M$126.4M$112.1M$104.9M$112.9M$105.3M$97.6M$89.2M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$532000$-7.2M$-13.9M$-11.8M$-4.2M$4.2M$-3.0M$-9.1M